Article
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia.
Bone marrow transplantation - 1 Feb 2025
Gui Gege, Ravindra Niveditha, Hegde Pranay S, Andrew Georgia, Mukherjee Devdeep, Wong Zoë, Auletta Jeffery J, El Chaer Firas, Chen Evan C, Chen Yi-Bin, Corner Adam, Devine Steven M, Iyer Sunil G, Jimenez Jimenez Antonio Martin, De Lima Marcos J G, Litzow Mark R, Kebriaei Partow, Saber Wael, Spellman Stephen R, Zeger Scott L, Page Kristin M, Dillon Laura W, Hourigan Christopher S
Abstract excerpt
Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.